Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Stacy L. Moulder"'
Autor:
Lei Huo, Abhinav K. Jain, Christopher Carroll, Jan Parker-Thornburg, Guillermina Lozano, Shirong Cai, Sabrina A. Stratton, Mihai Gagea, Michelle Craig Barton, Yan Jiang, Clifford Stephan, Michael Z. Gilcrease, Xinhui Zhou, Patrick M. Krause, Vrutant Shah, Lei Guo, Xiaomei Zhang, Stacy L. Moulder, Shiming Jiang, Peter J.A. Davies, Aundrietta D. Duncan, Helen Piwnica-Worms, Jianjun Shen, Clinton Yam, Richard R. Behringer, Zhijun Kang, Reid T. Powell, Bin Liu, Kendra Allton, Yue Lu, Yizheng Tu, Sebastian M. Manu, Jeffrey T. Chang
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Conditional overexpression of histone reader Tripartite motif containing protein 24 (TRIM24) in mouse mammary epithelia (Trim24COE) drives spontaneous development of mammary carcinosarcoma tumors, lacking ER, PR and HER2. Human carcinosarcomas or met
Autor:
Helen Piwnica-Worms, Stacy L. Moulder, Jenny C. Chang, Tejaswini P. Reddy, Roberto R. Rosato, Xiaoxian Li
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 22, Iss 1, Pp 1-11 (2020)
Breast Cancer Research, Vol 22, Iss 1, Pp 1-11 (2020)
Metaplastic breast cancer (MpBC) is an exceedingly rare breast cancer variant that is therapeutically challenging and aggressive. MpBC is defined by the histological presence of at least two cellular types, typically epithelial and mesenchymal compon
Autor:
Banu Arun, Bora Lim, Debu Tripathy, Senthil Damodaran, Jianhua Zhang, Elizabeth A. Mittendorf, Lumarie Santiago, Beatriz E. Adrada, Reva Basho, Jennifer K. Litton, Li Zhao, Elizabeth Ravenberg, Alastair M. Thompson, Jason B White, Lei Huo, Stacy L. Moulder, Clinton Yam, Vicente Valero
Publikováno v:
Journal of Clinical Oncology. 38:561-561
561 Background: Limited cell line and human data suggest that TNBCs characterized as mesenchymal and luminal androgen receptor (LAR) commonly have alterations in the PI3K pathway. More data is needed to better characterize the role of the PI3K pathwa
Autor:
Razelle Kurzrock, Philip J. Stephens, Roman Yelensky, Johnique T. Atkins, V. Valero, V.A. Miller, Filip Janku, Siqing Fu, David S. Hong, Ralph Zinner, Stacy L. Moulder, Sarina Anne Piha-Paul, Gerald S. Falchook, Aung Naing, Apostolia Maria Tsimberidou, Funda Meric-Bernstam, Jennifer J. Wheler
Publikováno v:
Cancer Research. 75:P2-05
Background Combining aromatase inhibitors with PI3K/AKT/mTOR inhibitors in patients with hormone receptor (HR)-positive metastatic breast cancer has demonstrated clinical efficacy. There is limited data on associations between molecular signatures an
Autor:
Hannah Dzimitrowicz, Gary A. Palmer, Baliang Wang, Kai Wang, Philip J. Stephens, W. Fraser Symmans, Neil Vasan, Stacy L. Moulder, Roman Yelensky, Rony Avritscher, Lajos Pusztai, Vincent A. Miller, Yun Wu, Maureen T. Cronin
Publikováno v:
The Oncologist. 19:453-458
Background. The aim of this study was to assess the frequency of potentially actionable genomic alterations in breast cancer that could be targeted with approved agents or investigational drugs in clinical trials using a next-generation sequencing-ba
Autor:
Aung Naing, Jennifer J. Wheler, Filip Janku, Rajyalakshmi Luthra, J. Jack Lee, Razelle Kurzrock, Russell Broaddus, Siqing Fu, Apostolia Maria Tsimberidou, Ralph Zinner, David S. Hong, Vanda M. Stepanek, Gerald S. Falchook, Sarina Anne Piha-Paul, Stacy L. Moulder
Publikováno v:
Cell Reports, Vol 6, Iss 2, Pp 377-387 (2014)
SummaryDespite a wealth of preclinical studies, it is unclear whether PIK3CA or phosphatase and tensin homolog (PTEN) gene aberrations are actionable in the clinical setting. Of 1,656 patients with advanced, refractory cancers tested for PIK3CA or PT
Autor:
Funda Meric-Bernstam, Razelle Kurzrock, Vivek Subbiah, Rashmi Krishna Murthy, Kenneth R. Hess, Mariana Chavez-MacGregor, Stacy L. Moulder, Kimberly B. Koenig, James L. Murray, Nuhad K. Ibrahim, David S. Hong, Daniel D. Karp, Reva K. Basho, Shelley M. Herbrich, Vicente Valero, Thorunn Helgason, Filip Janku, Constance Albarracin, Michael Z. Gilcrease, Jennifer K. Litton
Publikováno v:
JAMA oncology. 3(4)
Importance Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to en
Autor:
Ken Chen, Shannon N. Westin, Michael Frumovitz, Tae-Beom Kim, Anil K. Sood, Amir A. Jazaeri, Robert L. Coleman, Karen H. Lu, Marilyne Labrie, Stacy L. Moulder, Zhenlin Ju, Larissa A. Meyer, Sanghoon Lee, Jennifer K. Litton, Gordon B. Mills, Pamela T. Soliman
Publikováno v:
Cancer Research. 79:2070-2070
Introduction: The objective was to identify molecular mechanisms and protein networks involved in synthetic lethality as well as mechanisms of adaptive changes to the combination of olaparib (O) combined with inhibitors of the PI3K-AKT axis. Methods:
Autor:
Marilyne Labrie, Ken Chen, Anil K. Sood, Michael Frumovitz, Shannon N. Westin, Jennifer K. Litton, Karen H. Lu, GB Mills, Amir A. Jazaeri, Stacy L. Moulder, Sun Joo Lee, Zhenlin Ju, Pamela T. Soliman, Robert L. Coleman, Larissa A. Meyer, Tae-Beom Kim
Publikováno v:
Gynecologic Oncology. 154:60
Autor:
Vicente Valero, Filip Janku, Stacy L. Moulder, Jennifer J. Wheler, Vincent A. Miller, Razelle Kurzrock, Funda Meric-Bernstam, Roman Yelensky, Philip J. Stephens, Johnique T. Atkins
Publikováno v:
Oncoscience
Oncoscience, vol 3, iss 5-6
Wheler, JJ; Atkins, JT; Janku, F; Moulder, SL; Stephens, PJ; Yelensky, R; et al.(2016). Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.. Oncoscience, 3(5-6), 164-172. doi: 10.18632/oncoscience.307. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/3j34k51b
Oncoscience, vol 3, iss 5-6
Wheler, JJ; Atkins, JT; Janku, F; Moulder, SL; Stephens, PJ; Yelensky, R; et al.(2016). Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.. Oncoscience, 3(5-6), 164-172. doi: 10.18632/oncoscience.307. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/3j34k51b
There is limited data on co-expression of FGFR/FGR amplifications and PI3K/ AKT/mTOR alterations in breast cancer. Tumors from patients with metastatic breast cancer referred to our Phase I Program were analyzed by next generation sequencing (NGS). G